

*Review Article*

## **Atopic Dermatitis: Drug Delivery (Management) and Approaches (Strategies) in Perspective**

*Virendra N. Sehgal*

Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home,  
Panchwati, Delhi.

### **ABSTRACT**

Age-related cutaneous manifestations are definitive pointer to the diagnosis of atopic dermatitis, the confirmation of which is solicited by 3 major and 3 minor criteria. Its unpredictable course is punctuated by exacerbations and remissions. Several treatment options, namely: 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> line are in vogue ever since. The 1<sup>st</sup> line envisages general measures, 2<sup>nd</sup> encompasses topical applications, while the 3<sup>rd</sup> take into account drug therapy comprising, systemic Corticosteroids, Cyclosporin, Azathioprine, Thymopentin, Interferon-therapy, Topical Calcineurin inhibitors: Tacrolimus and Pimecrolimus. The mode of action, their dosages and adverse drug reaction (ADR), in particular, have been focused in this paper with special attention to refresh their drug delivery (management) approaches (strategies) in perspective. An endeavor to focus attention to emerging etio-pathogenesis, and its application in the contemporary context has also been made.

*Keywords:* Atopic dermatitis, Immunoglobulins E, Cyclosporin, Azathioprine, Thymopentin, Interferon-therapy.

### **Introduction**

Atopic dermatitis (AD) is a non-contagious, intensely pruritic, inflammatory, chronic skin disorder having a course of exacerbations and remissions, occurring in infancy and childhood running in families with a history of atopy. It is frequently associated with an elevated immunoglobulins E (IgE) levels in serum. Disease has an intricate immunological basis influenced by genetic/ familial predisposition, and certain environmental, life style and dietary factors. Recent trends suggest a continuous rise in the prevalence of atopic dermatitis in developed nations and in countries undergoing rapid urbanization and industrialization. The

clinical phenotype that characterizes AD as the product of complex interactions among susceptibility genes, the host's environment, defects in skin barrier function, and systemic and local immunologic responses (1-4). IgE discovered in 1966 by the Japanese scientist couple Teruka and Kimishige Ishizaka (5), plays an important role in allergy, and is especially associated with type 1 hypersensitivity.

Serum IgE levels in a normal, non-atopic individual are only 0.05 percent of the IgG concentration, the isotype responsible for most of the classical adaptive immune response (6). Although IgE is typically the least abundant

isotype, it is capable of triggering the most powerful immune reactions. Increased serum levels of IgE have subsequently been reported in patients with asthma, hay fever, atopic dermatitis (7-9) and also in patients infested with intestinal parasites (7). In several studies the concentrations of other immunoglobulin classes have been investigated in atopic subjects. Varelzidis *et al* (10) found a significant rise in the level of IgG in a study of adults and children with atopic eczema. High serum levels of IgA in atopic subjects have been described by Ortiz (11). Drug delivery approaches (12), in particular, are adopted for largely it takes into account formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effect.

### **Drug Delivery (Management) Approaches (Strategies)**

Due to variations in presentation in different age groups and severity of the disorder, the therapy has to be individualized. The treatment of AD envisages reducing symptoms, preventing exacerbations and recurrences, and minimizing side-effects from medications. The use of emollients, wet dressings, topical corticosteroids, antibiotics for infections, antihistamines, stress management, counseling and avoidance of allergens or triggers (1) are its main stay, the brief of treatment modalities (13) are recounted below:

#### **A. First (1<sup>st</sup>) Line Therapy**

- a. General advice - decreasing scratching, improving family interaction, correcting sleep disturbances, and avoidance of trigger factors.
- b. Reduction of trigger factors
  - i. Curtail use of Soap and detergent
  - ii. Avoid contact with wool
  - iii. A central or room humidifier may help in obviating xerosis
  - iv. Eliminate air borne allergens
  - v. Avoid house pets
  - vi. Alleviate patient and/or family stress

- c. Topical therapy
  - i. Bathing followed by emollients, moisturizing creams and emollients are useful and important treatment adjuncts for the daily skin care of patients with dry and inflamed skin
  - ii. Initial administration of mild/mid potent topical steroids
  - iii. Maintenance by ichthammol /coal tar
- d. Systemic therapy
  - i. Oral antihistaminic therapy comprising hydroxyzin hydrochloride / dihydrochloride at bed time, and antibiotics when impetigo develops.

#### **B. Second (2<sup>nd</sup>) Line Therapy**

- a. Intensive topical potent corticosteroids for short periods
- b. Wet-wrap techniques: affected parts covered with emollient followed by a wet inner and dry outer dressing used over night
- c. Contact allergy to medicaments is possible, change to different preparations or patch test to topical agents.
- d. Phototherapy, a useful treatment option in moderate to severe, resistant disease which frequently needs systemic immunosuppressive.

PUVA is recognized to be beneficial in the management of adult AD, and children over 12 years of age. Narrowband UVB (14) is preferred in pediatric age group. Limitations are visits to treatment center and risk of premature skin aging and cutaneous malignancies.

#### **C. Third (3<sup>rd</sup>) Line Therapy Drugs**

##### *Systemic corticosteroid*

Acute flare-up, in patients of AD may benefit from a short course of systemic therapy with corticosteroids (15, 16), but long-term use in adults and any use in children should be avoided.

### ***Cyclosporin***

Cyclosporin (CSA) is an immunosuppressant drug widely used in organ transplantation to prevent rejection (17, 18). It reduces the activity of the immune system by interfering with the activity and growth of T cells (19). T-cell receptor activation causes release of intracellular calcium that in turn binds to calmodulin, and activates calcineurin. The calcineurin complex then dephosphorylates the nuclear factor of activated T cells (NFATc), which migrate into the nucleus and make a complex that is a transcription factor for inflammatory cytokines, (e.g., IL-2). Cyclosporin binds to cyclophilin (intracytoplasmic proteins-immunophilin), which blocks the dephosphorylation of NFAT, resulting in a decrease of T-helper cells (CD4), and cytotoxic (CD8) in the epidermis. Cyclosporin A (CyA) inhibits calcineurin-dependent pathways, resulting in reduced levels of pro-inflammatory cytokines, such as IL-2 and IFN- $\gamma$ . CyA is effective in treatment for both adult and childhood AD (20). It is an isolate from *Tolypocladium inflatum*, the fungus found in a soil samples (21). It is a cyclic non-ribosomal peptide of 11 amino acids, and contains a single D-amino acid, rarely encountered in nature (22).

#### *Dosage schedule*

Unresponsive atopic dermatitis to topical therapy may require high-dose comprising 5 mg/kg/day divided into two doses of CSA as an acute management strategy for a period of 6 weeks, followed by randomization to receive maintenance treatment with either CSA 3 mg/kg/day or enteric-coated mycophenolate sodium (1440 mg/day) for 30 weeks, followed by a 12-week follow-up period (23, 24). However, for long term treatment lowest effective dose is recommended (25).

#### *Adverse drug reactions (ADRs) of CSA are (26)*

- Enlargement of the gums
- Convulsions

- Peptic ulcers
- Pancreatitis
- Fever,
- Vomiting
- Diarrhea
- Confusion
- Hypercholesterolemia,
- Dyspnea
- Numbness and tingling particularly of the lips
- Pruritus
- High blood pressure, potassium retention possibly leading to hyperkalemia
- Kidney and liver dysfunction (nephrotoxicity) and hepatotoxicity

### ***Azathioprine***

Azathioprine (AZA) Imuran, is an immunosuppressive drug used in organ transplantation, and autoimmune diseases including atopic dermatitis (27-29). It belongs to the chemical class of purine analogues (29).

#### *Dosage schedule*

Usual pediatric dose for atopic dermatitis in patients greater than 17 years: 2.5 mg/kg orally once a day, in the morning, for 3 months.

#### *Adverse drug reactions (ADRs)*

It has several side-effects including myelosuppression, hepatotoxicity, and susceptibility for infection (30).

### ***Thymopentin* (31-38)**

Thymopentin (31) an immuno-stimulant (32), is a thymic polypeptide (33), which interacts with T cells (34, 35), causing T-helper cell activation resulting in enhanced interleukin-2 production with subsequent proliferation of cytotoxic T lymphocytes and natural killer cells which are capable of producing immune interferon (36), thus helps to improve

immunological condition(s) including atopic dermatitis (37).

#### *Dosage schedule*

Thymopentin therapy reduces the clinical severity of atopic dermatitis at a dose of 1 mg/kg, three times per week for 8 weeks (38, 39).

#### *Adverse drug reactions (ADRs)*

No significant adverse drug reactions are noticed, except for an increase in the T-helper/ T-suppressor ratio.

#### ***Interferon–therapy*** (40-48)

Interferons (IFNs) (40) are a group of signaling proteins (41), the cytokines, molecules used for communication between cells to trigger the protective defenses of the immune system that help eradicate pathogens such as viruses, bacteria, and parasites. Interferons are named for their ability to interfere with viral replication by protecting cells from virus infections (42). Their other functions are to activate immune cells, such as natural killer cells and macrophages; they increase host defenses by up-regulating antigen presentation by virtue of increasing the expression of major histocompatibility complex (MHC) antigens. Certain symptoms of infections; fever, muscle pain and flu-like symptoms, are also caused by the production of IFNs and other cytokines. Currently, AD is classified into Extrinsic atopic dermatitis (eAD ) (43), IgE associated allergic atopic dermatitis, and Intrinsic atopic dermatitis (iAD), non-allergic atopic eczema/dermatitis syndrome (AEDS) (44). eAD has elevated Th2- and decreased Th1-expressing cells in the peripheral blood, with elevated interleukin (IL-4 and IL-13) expression, increased, IgE levels and decreased IFN-gamma production. Accordingly, it is imperative to highlight the role of recombinant interferon-gamma therapy in severe atopic dermatitis (45-47).

#### *Dosage schedule*

50 micrograms/m<sup>2</sup> rIFN-gamma (n = 40) or placebo (n = 43) by daily subcutaneous injection for 12 weeks.

#### *Adverse drug reactions* (48, 49)

- Early: Flu-like syndrome : Fever, chills, generalized aches and pains, headache, poor appetite.
- Fatigue, drowsiness.
- Low blood counts

#### **Topical immunosuppressant** (50-64)

##### **Calcineurin inhibitors**

- **Tacrolimus** (50)

Tacrolimus (FK506), a macrolide lactone produced by soil fungus *Streptomyces tsukubaensis*. It was originally used intravenously or orally for prevention of organ rejection after transplant. Tacrolimus, especially through the topical route of administration, gained entry into therapy for inflammatory dermatoses (51), such as atopic dermatitis, without significant risk of toxicity (47). The use of tacrolimus (53, 54) (Prograf) and pimecrolimus (55) (Elidel) ointments has been licensed in the UK since 2001 subject to National Institute for Health and Clinical Excellence guidance. Tacrolimus ointment is restricted to use in adults (0.1%) and children over 2 years of age (0.03%) with moderate to severe atopic dermatitis not controlled by topical corticosteroids. Pimecrolimus cream is for use in corticosteroid resistant facial dermatitis. They are perceived as second-line agents, but conditions of use vary.

Many studies have demonstrated their efficacy, and their attraction is the absence of the cutaneous side-effects, atrophy of skin, striae, telangiectasia and bruising that may be seen with prolonged or inappropriate corticosteroid use (56). The US Food and Drug Administration



(FDA), however, has warned of their injudicious use due to theoretic side-effects (57) related to immuno-suppressant, including cutaneous or internal malignancies children.

A pilot study (58) was initiated to evaluate the efficacy of tacrolimus 0.1% ointment in the treatment of atopic hand eczema (AHE). The study was an open-label non-comparative using tacrolimus 0.1% ointment in 10 patients with AHE. Inclusion criteria included patients with hand eczema, known history of atopy, AD, hay fever and/or asthma. Patients had to stop topical application of steroids and systemic use of steroids or antihistamines for 4 weeks. Patients applied tacrolimus 0.1% ointment twice daily for 4 weeks. Evaluation was performed before treatment, after 4 weeks of treatment, and after a follow-up period of 4 weeks. During follow-up, the patients used emollients. Treatment efficacy was established at each visit based on the following parameters: itch and/or burning sensation, dryness, erythema, lichenification, erosions and fissures. Of the 10 patients, four had marked or complete improvement at the end of treatment, four other cases had partial improvement, while in one patient the treatment failed. One patient left the study due to side-effects.

#### • **Pimecrolimus (59)**

Pimecrolimus is an ascomycin macrolactam derivative, which has a potential to bind to macrophilin-12 (FKBP-12) *in vitro* and inhibits calcineurin. Thus it inhibits T-cell activation by inhibiting the synthesis, and release of cytokines from T-cells. It also prevents the release of inflammatory cytokines and mediators from mast cells (60-64).

#### **Azathioprine and Betamethasone versus Betamethasone Therapy (65)**

Efficacy of combine topical emollients containing azathioprine (AZT) and betamethasone (BM), and betamethasone alone was used in two groups of moderate-to-severe

atopic dermatitis, twice a day for a period of 8 weeks. The recurrence, and presence of side-effects were evaluated, the former was found to be superior in contrast to betamethasone, suggesting usefulness of AZT in the future dispensation (65).

#### **Topical Therapy, Evolving Scenario (66-76)**

Although, several treatment options are in vogue, its treatment continues to loom large, because its etio-pathogenesis is largely seem to be enigmatic (66, 67) nevertheless, the endeavors to unfold it are relentlessly continuing. The advent of stratum corneum (66, 68), the impeccable skin barrier has taken the central stage. Accordingly, its micro-anatomy (structure) and physiology (function) has added refreshing dimensions. The alterations in its patho-physiology have been a definitive step forward, enshrining the role of flaggrin (69) and serine proteases (70) in particular. The changing pattern in the former may impede its physical strength, hydration status, skin pH, and buffering capacity amongst other physio-chemical properties. Filaggrin (71, 72), the epidermal barrier protein is, therefore, a major pre-disposing factor in the pathogenesis of AD. In addition, up-regulation of serine protease activity may cause adverse structural changes due to degradation of certain proteins, the part component of epidermal structure and its functions, thus interfering in the formation of the stratum corneum intercellular lipid membrane, regulating epidermal water flux and gradient, resulting in induction of TH2 (Subset Type pattern) of inflammation. Simultaneous, immune system (73) and its dysfunction through IgE mediated sequence of events capped by genetic (74) undertones may initiate and/or perpetuate the clinical expression of AD. Hence, the preceding rumblings responsible for the clinical connotation of AD, may bring to the fore

newer modalities to counter the intricate often difficult to treat condition. Thus, atopic dermatitis treatment envisages (75).

- Eliminating inflammation and infection
- Hydrating the skin
- Controlling pruritus, and
- Avoiding exacerbative factors

Addition of moisturizer to a low-potency corticosteroid lotion in separate regimens is effective in treating the signs and symptoms of mild-to-moderate atopic dermatitis (75, 76).

### **Bathing and Emollients (77-80)**

Foaming detergents and soaps should be avoided. A soap substitute should be used for cleansing (77-78). A regular use of emollient(s) may even protect against inflammation provoked by irritants, thus increasing the benefit obtained from topical corticosteroid therapy (79). Indeed, ceramide-rich emollients may lead to improvements in childhood atopic dermatitis through a specific barrier repair mechanism (80).

### **Topical Suppression of Inflammation (81)**

Topical steroids are the predominant treatment for the inflammation of atopic dermatitis, and are very safe. The strength and mode of application of the topical steroids may depend on the severity of the dermatitis, the site(s) and the age of the patient. Less potent topical steroids should be used on the eyelid, face, axillae, groins and inner thighs. Less potent topical steroids are used in less than 1 year old children. Systemic absorption may occur, even with 1% hydrocortisone ointment. It is therefore recommended to apply the ointment once daily in the evening, morning application of emollients, may be effective. There appear to be no differences in efficacy or side-effects between pulsed potent corticosteroid creams and the continuous use of mild topical corticosteroids in patients with mild to moderate disease (81).

## **Antipruritic Agents (82-84)**

### **1. Antihistamines (82-84)**

H1-receptor antagonists (82) are used predominantly for their sedative effect. Agents such as promethazine or trimeprazine given 1 h before bedtime can be useful when there is severe nocturnal itching. However, they can cause drowsiness and lack of concentration the next morning. In infants, these preparations may occasionally cause paradoxical excitation. They are best used in short courses, for example 10–14 days, as tachyphylaxis can occur with prolonged use (83). Most studies (84) concluded that non-sedating antihistamines are of little value for the pruritus of atopic dermatitis

### **2. Antibiotics (85-87)**

Systemic antibiotic treatment is indicated for widespread bacterial secondary infection, primarily *S. aureus*. First- or second-generation cephalosporins or semi-synthetic penicillins administered for 7 to 10 days are usually effective. Clindamycin or oral fusidic acid (85) are possible alternatives in cases of penicillin or cephalosporin allergy. Besides, heavy colonization of *klebsiella pneumonia* (86) may also be recovered, requiring administration of metronidazole specific for anaerobic gram negative bacteria (87).

### **3. Leukotriene Antagonists (88)**

Leukotriene antagonists (montelukast and zafirlukast) are useful for the treatment of asthma and allergic rhinitis. In AD therapy they are not fully elucidated. Zafirlukast (Accolate) is approved in AD and asthma for adolescents, and adult. In chronic AD montelukast (Singulair) achieved little success. It is administered in the doses of 5mg daily for 4 weeks in a clinical double-blind study (88) of moderate to severe AD in young patients between 6 to 16 years showed a significant decrease in disclosed severity, but in another study with severe AD and different doses of 5 mg, 10 mg, 20 mg, a partial

improvement comprising relief of pruritus; and erythema, in a few patients. AD patients *per se* failed to show any benefit from leukotriene receptor antagonist therapy.

### Phototherapy

**Phototherapy** options namely:

- broad-band UVB (280 to 320 nm)
- narrowband UVB (311 to 313 nm),
- UVA (320 to 400 nm), UVA1 (340 to 400 nm)
- PUVA, and PUVA bath
- Combinations of UVB, TCs and UVB with UVA as well as UVA1

Medium- and high dose therapy are useful in AD. In the pediatric population, UV therapy should be restricted to children older than 12 (89)

### Bioengineered Immuno-modulators (90)

Most of the new approaches aim at inhibiting components of the allergic inflammatory response, including cytokine modulation, the tumor necrosis factor [TNF] inhibitors, blockade of inflammatory cell recruitment, the chemokine receptor antagonists, cutaneous lymphocyte antigen inhibitors, and inhibition of T-cell activation (alefacept and efalizumab). Currently, bioengineered immune- modulators are in a clinical trial phase for AD treatment (90).

### IgE-blocking Antibody (91)

IgE-blocking antibody omalizumab is a recombinant human monoclonal antibody that targets specific antihuman IgE drugs, which binds free serum IgE and avoids binding to Fc3RI receptors as well as Fc3RII [CD23] receptors on mast cells, basophiles, and antigen-presenting cell surfaces, which stops release of pro-inflammatory mediators.

Omalizumab is for use in adults and children older than 12 years with asthma and AD for 3 months; subcutaneous injections of 0.015 mg/kg IgE and 0.03 mg/kg each 2 weeks or 4 weeks. The role of omalizumab in dermatology and for AD is probably best directed towards patients who have high levels of IgE, and in whom the IgE is an etiologic factor for their disease (91).

### Probiotics (92, 93)

They have also been tried in AD. Probiotics are cultures of potentially beneficial bacteria that positively affect hosts with adverse reactions to certain foods, as may be the case in AD. Many interventional studies have reported variable outcomes with manipulation of diet and environment in pregnant women, the primary prevention, and children with established AD, the secondary prevention. However, more work is required to determine the effect of such measures on the long-term outlook of patients with AD. Early treatment with microbial probiotics may be beneficial by boosting Th1 immune responses in AD (92, 93).

It is difficult to predict the outcome of the disease. It is found to be more persistent and prevalent in young children, the episodes of remission become more frequent and of longer duration in an aging child. A spontaneous remission after the age of 5 may be observed in 40 to 60 percent of patients who develop the disease in infancy. A poor prognosis is seen in individuals who have widespread disease in childhood, associated rhinitis/asthma, a positive family history, and/or very high serum IgE levels (1).

### References

1. Sehgal V N, Srivastava G, Dogra S (2010). Atopic dermatitis: current options and treatment plans. *Skinmed* **8**: 335-344.
2. Staab D, Diepgen TL, Fartasch M, *et al* (2006). Age-related structured educational programmes for the management of atopic

- dermatitis in children and adolescents: multicentre, randomised controlled trial. *Br Med J* **332**: 933–938.
3. Anonymous (2005). Atopic eczema - new insights in the definition, diagnostics and disease management. Proceedings of a LEO eczema workshop. November 2003. Copenhagen, Denmark. *Acta Derm Venereol Suppl (Stockh)* **215**: 7–48.
  4. Anonymous (2005). Consensus conference management of atopic dermatitis in children. Recommendations (short version). *Eur J Dermatol* **15**: 215–223.
  5. Ishizaka K, Ishizaka T, Hornbrook MM (1966). Physicochemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. *J Immunol* **97**(1): 75–85.
  6. Winter WE, Hardt NS, Fuhrman S (2000). IgE–importance in parasitic infections and hypersensitivity responses. *Arch Pathol Lab Med* **124**: 1382–1385.
  7. Bennich H, Johansson SGO (1971). Structure and function of human Immunoglobulin E. *Adv Immunol* **13**: 1–55.
  8. Berg T, Johansson SG (1969). IgE concentrations in children with atopic diseases. *Intl Arch Allergy* **36**: 219–232.
  9. Juhlin L, Johansson SGO, Bennich H, *et al* (1969). IgE in dermatoses. *Arch Dermatol* **100**: 12–16.
  10. Varelzidis A, Wilson AB, Meara RH, *et al* (1966). Immunoglobulin levels in atopic eczema. *Br Med J* **2**: 925–927.
  11. Ortiz F (1968). Serum levels of IgA in atopic patients. *Allerg Asthma (Leipz)* **14**: 116–122.
  12. Tiwari G, Tiwari R, Sriwastawa B, *et al* (2012). Drug delivery systems: an updated review. *Intl J Pharm Investig* **2**: 2–11.
  13. Boguniewicz M, Eichenfield LF, Hultsch T (2003). Current management of atopic dermatitis and interruption of the atopic march. *J Allergy Clin Immunol* **112**: 140–150.
  14. George SA, Bilsland DJ, Johnson BE, *et al* (1993). Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. *Br J Dermatol* **128**: 49–56.
  15. Galli E, Chini L, Moschese V *et al* (1994). Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. *Acta Paediatr* **83**: 315–317.
  16. Lipozencic J, Wolf R (2007). Atopic dermatitis: an update and review of the literature. *Dermatol Clin* **25**: 605–612.
  17. Munro CS, Levell NJ, Shuster S, *et al* (1994). Maintenance treatment with cyclosporine in atopic dermatitis. *Br J Dermatol* **130**: 376–380.
  18. Anonymous (2011). Cyclosporin. *Dictionary.com Un-abridged*. Random House. n.d. Archived from the original on 2010-11-18. Retrieved 2011-07-13.
  19. Cantrell DA, Smith KA (1984). The interleukin-2 T-cell system: a new cell growth model. *Science* **224**: 1312–1316.
  20. Wolverson S, Darst M (2003). Systemic drugs. In: *Dermatology*. Bologna JL, Jorizzo JL, Rapini RP, eds. Edinburgh (Scotland): Mosby, 2071–2077.
  21. Svarstad H, Bugge HC, Dhillion SS (2009). From Norway to Novartis: Cyclosporin from *Tolypocladium inflatum* in an open access bioprospecting regime. *Biodiversity Conservation* **9**: 1521–1541.
  22. Borel JF (2002). History of the discovery of cyclosporin and of its early pharmacological development. *Wien Klin Wochenschr* **114**: 433–437.
  23. Denby KS, Beck LA (2012). Update on systemic therapies for atopic dermatitis. *Curr Opin Allergy Clin Immunol* **12**: 421–426.
  24. Czech W, Bräutigam M, Weidinger G, Schöpf E (2000). A body-weight-independent dosing regimen of cyclosporine



- microemulsion is effective in severe atopic dermatitis and improves the quality of life. *J Am Acad Dermatol* **42**: 653-659.
25. Robert N, Wong GW, Wright JM (2010). Effect of cyclosporine on blood pressure. *Cochrane Database Syst Rev*: CD007893.
  26. Naesens M, Kuypers DR, Sarwal M (2009). Calcineurin inhibitor nephrotoxicity. *Clin J Am Soc Nephrol* **4**: 481-509.
  27. Lear JT, English JS, Jones P, *et al* (1996). Retrospective review of the use of azathioprine in severe atopic dermatitis. *J Am Acad Dermatol* **35**: 642-643.
  28. Azathioprine. *Merriam-Webster Dictionary*.
  29. American Society of Health-System Pharmacists . Azathioprine, Azathioprine Sodium. *AHFS Drug Information 2012*. American Society of Health-System Pharmacists.
  30. Fields CL, Robinson JW, Roy TM, Ossorio MA, Byrd RP Jr (1998). Hypersensitivity reaction to azathioprine. *South Med J* **91**: 471-474.
  31. Hsieh KH, Shaio MF, Liao TN (1992). Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations. *Arch Dis Child* **67**: 1095-1102.
  32. Mascart-Lemone F, Huygen K, Clumeck N, Benez D, Bolla K, Duchateau J (1983). Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients. *Lancet* **322**: 735-736.
  33. Peng Y, Chen Z, Yu W, *et al* (2008). Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. *Cell Biol Intl* **32**: 1265-1271.
  34. Goldstein G, Audhya TK (1985). Thymopoietin to thymopentin: experimental studies. *Surv Immunol Res* **4** Suppl 1:1-10.
  35. Liu Z, Zheng X, Wang J, *et al* (2007). Molecular analysis of thymopentin binding to HLA-DR molecules. *PLoS ONE* **2**: e1348.
  36. Haneke E, Bolla K, Degreef H, *et al* (1984). The effect of thymopentin treatment on the relapse rate in frequently relapsing herpes simplex virus infections. *Intl J Clin Pharmacol Res* **4**: 439-443.
  37. Stiller MJ, Shupack JL, Kenny C, *et al* (1994). A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. *J Am Acad Dermatol* **30**: 597-602.
  38. Leung DY, Hirsch RL, Schneider L, *et al* (1990). Thymopentin therapy reduces the clinical severity of atopic dermatitis. *J Allergy Clin Immunol* **85**: 927-933.
  39. Noh GW, Lee KY (1998). Korean thymopentin therapy in atopic dermatitis. *J Pediatr* **41**: 1268-1272.
  40. De Weerd NA, Samarajiwa SA, Hertzog PJ (2007). Type I interferon receptors: biochemistry and biological functions. *J Biol Chem* **282**: 20053-20057.
  41. De Andrea M, Ravera R, Gioia D, Gariglio M, Landolfo S (2002). The interferon system: an overview. *Eur J Paediatr Neurol* **6** Suppl A: A41-A56.
  42. Cohen B, Parkin J (2001). An overview of the immune system. *Lancet* **357**: 1777-1789.
  43. Wüthrich B, Schmid-Grendelmeier P (2003). The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic") AEDS. *J Investig Allergol Clin Immunol* **13**: 1-5.
  44. Schmid-Grendelmeier P, Simon D, Simon HU, *et al* (2001). Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). *Allergy* **56**: 841-849.
  45. Reinhold U, Kukel S, Brzoska J, Kreysel HW (1993). Systemic interferon gamma

- treatment in severe atopic dermatitis. *J Am Acad Dermatol* **29**: 58-63.
46. Chang TT, Stevens SR (2002). Atopic dermatitis: the role of recombinant interferon-gamma therapy. *Am J Clin Dermatol* **3**:175-183.
  47. Schneider LC, Baz Z, Zarccone C, Zurakowski D (1998). Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis. *Ann Allergy Asthma Immunol* **80**: 263-268.
  48. Sleijfer S, Bannink M, Van Gool AR, *et al* (2005). Side effects of interferon-alpha therapy. *Pharm World Sci* **27**: 423-431.
  49. Berman B, De Araujo T, Lebwohl M (2003). Immunomodulators. In: *Dermatology*. Bologna JL, Jorizzo JL, Rapini RP, eds. Edinburgh (Scotland): Mosby, 2033–2053.
  50. Kapp A, Allen BR, Reitamo S (2003). Atopic dermatitis management with tacrolimus ointment. *J Dermatol Treat* **14**: 5–16.
  51. Contreras Ruiz J, Kerdel FA (2004). Tacrolimus (FK-506). In: *Drug Therapy in Dermatology*, 1st edn. Millikan LE, ed. New York NY: Marcel Dekkar Inc, 161-170.
  52. Ruzicka T, Bieber T, Schöpf E, *et al* (1997). A short-term trial of tacrolimus ointment for atopic dermatitis. *N Engl J Med* **337**: 816–821.
  53. Sehgal VN, Srivastava G, Dogra S (2008). Tacrolimus in dermatology—pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I. *Skinmed* **7**: 27-30.
  54. Sehgal VN, Srivastava G, Dogra S (2008). Tacrolimus: approved and unapproved dermatologic indications/uses—physician's sequential literature survey: part II. *Skinmed* **7**: 73-77.
  55. Sehgal VN, Pahwa M (2007). Pimecrolimus, yet another intriguing topical immunomodulator. *J Dermatolog Treat* **18**: 147-150.
  56. Ashcroft DM, Dimmock P, Garside R, *et al* (2005). Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. *Br Med J* **330**: 516–522.
  57. FDA (2006). FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic P06-09 January 19, 2006 <https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm153941.htm>.
  58. Shri J, Amichai B (2006). Tacrolimus ointment in the treatment of atopic hand eczema. *Indian J Dermatol* **51**: 66-67.
  59. Meurer M, Folster-Holst R, Wozel G, *et al* (2002). Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. *Dermatology* **205**: 271-277.
  60. Billich A, Aschauer H, Aszódi A, Stuetz A (2004). Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. *Intl J Pharm* **269**: 29–35.
  61. Huang X, Xu B (2015). Efficacy and safety of tacrolimus versus pimecrolimus for the treatment of atopic dermatitis in children: a network meta-analysis. *Dermatology* **231**: 41-49.
  62. Werfel T (2009). Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy. *J Dtsch Dermatol Ges* **7**: 739-742.
  63. Lee HH, Zuberbier T, Worm M (2007). Treatment of atopic dermatitis with pimecrolimus – impact on quality of life. *Ther Clin Risk Manag* **3**: 1021–1026.
  64. Luger T, Boguniewicz M, Carr W (2015). Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use

- in infants. *Pediatr Allergy Immunol* **26**: 306-315.
65. Iraj F, Farhadi S, Faghini G, *et al* (2015). Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: a randomized controlled trial. *Adv Biomed Res* **4**: 228.
  66. Rerknimitr P, Otsuka A, Nakashima C, Kabashima K (2017). The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. *Inflamm Regen* **37**:14. <https://doi.org/10.1186/s41232-017-0044-7>.
  67. Sehgal VN, Khurana A, Mendiratta V, *et al* (2015). Atopic dermatitis; etio-pathogenesis, an overview. *Indian J Dermatol* **60**: 327-331.
  68. Elias PM, Hatano Y, Williams ML (2008). Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. *J Allergy Clin Immunol* **121**:1337–1343.
  69. Levin J, Friedlander SF, Del Rosso JQ, *et al* (2013). Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. *J Clin Aesthet Dermatol* **6**: 16–22.
  70. Ovaere P, Lippens S, Vandenabeele P, Declercq W (2009). The emerging roles of serine protease cascades in the epidermis. *Trends Biochem Sci* **34**: 453–463.
  71. Markova NG, Marekov LN, Chipev CC, *et al* (1993). Profilaggrin is a major epidermal calcium-binding protein. *Mol Cell Biol* **13**: 613–625.
  72. Palmer CN, Irvine AD, Terron-Kwiatkowski A, *et al* (2006). Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet* **38**: 441-446.
  73. Miraglia del Giudice M, Decimo F, Leonardi S, *et al* (2006). Immune dysregulation in atopic dermatitis. *Allergy Asthma Proc* **27**: 451-455.
  74. An update on the genetics of atopic dermatitis: scratching the surface in 2009. *J Allergy Clin Immunol* **125**: 16–31.
  75. Schnopp C, Holtmann C, Stock S, *et al* (2002). Topical steroids under wet-wrap dressings in atopic dermatitis-a vehicle-controlled trial. *Dermatology* **204**: 56–59.
  76. Hanifin JM, Hebert AA, Mays SR, *et al* (1998). Effects of a low-potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. *Curr Ther Res* **59**(4): 227–233.
  77. Anonymous (2007). Atopic Eczema in Children: Management of Atopic Eczema in Children from Birth up to the Age of 12 Years. NICE Clinical Guidelines, No. 57. National Collaborating Centre for Women's and Children's Health (UK). London: RCOG Press.
  78. Loden M, Andersson A-C (1996). Effect of topically applied lipids on surfactant irritated skin. *Br J Dermatol* **134**: 215–220.
  79. Grimault R, Mengeaud V, Cambazard F (2007). The steroid sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. *Dermatology (Basel)* **214**: 61–67.
  80. Chamlin SL, Frieden IJ, Fowler A, *et al* (2001). Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. *Arch Dermatol* **137**: 1110–1112.
  81. Thomas KS, Armstrong S, Avery A, *et al* (2002). Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild to moderate atopic eczema. *Br Med J* **324**: 768–771.
  82. Klein PA, Clark RA (1999). An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. *Arch Dermatol* **135**: 1522–1525.

83. Kemp JP (1989). Tolerance to antihistamines: is it a problem? *Ann Allergy* **63**:621–623.
84. Diepgen TL; Early treatment of the Atopic Child Study Group (2002). Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. *Pediatr Allergy Immunol* **13**: 278–286.
85. Lipozencic J, Wolf R (2007). Atopic dermatitis: an update and review of the literature. *Dermatol Clin* **25**: 605–612.
86. Sehgal VN, Sehgal D, Syed NH, Sharma S (2017). Erythroderma: an association or a manifestation extraordinary of hyper Immunoglobulin E. *Indian J Paediatr Dermatol* **18**: 306-309.
87. Martins IS, Pessoa-Silva CL, Nouer SA, *et al* (2006). Endemic extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* at an intensive care unit: risk factors for colonization and infection. *Microb Drug Resist* **12**: 50-58.
88. Mohrenschlager M, Darsow U, Schnopp C, *et al* (2006). Atopic eczema: what's new? *J Eur Acad Dermatol Venereol* **20**: 503–513.
89. Scheinfeld NS, Tutrone WD, Weinberg JM, *et al* (2003). Phototherapy of atopic dermatitis. *Clin Dermatol* **21**: 241–248.
90. Akdis CA, Akdis M, Bieber T, *et al*; European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology (2006). Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *J Allergy Clin Immunol* **118**:152-169.
91. Scheinfeld N (2005). Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody. *Dermatol Online J* **11**: 2.
92. Betsi GI, Papadavid E, Falagas ME (2008). Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. *Am J Clin Dermatol* **9**: 93–103.
93. Yeşilova Y, Çalka O, Akdeniz N, Berktaş M (2012). Effect of probiotics on the treatment of children with atopic dermatitis. *Ann Dermatol* **24**: 189–193.